Design Therapeutics advances DT-216P2 and reports Q2 2026 results
The company is advancing the RESTORE-FA trial for DT-216P2 and initiating dosing for its DM1 candidate, DT-818, with cash nearing $208 million. The stock is untraded and closed today.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day